TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

by · The Markets Daily

StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Free Report) in a report issued on Saturday. The firm issued a hold rating on the stock.

TherapeuticsMD Trading Up 1.8 %

NASDAQ:TXMD opened at $1.11 on Friday. TherapeuticsMD has a 12 month low of $1.05 and a 12 month high of $2.75. The firm has a fifty day simple moving average of $1.41 and a 200-day simple moving average of $1.64.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP boosted its position in TherapeuticsMD, Inc. (NASDAQ:TXMD – Free Report) by 18.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the period. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities & Exchange Commission. 30.74% of the stock is currently owned by institutional investors and hedge funds.

About TherapeuticsMD

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.

Further Reading